e-therapeutics Past Earnings Performance

Past criteria checks 0/6

e-therapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 16.1% annually. Revenues have been growing at an average rate of 22% per year.

Key information

-25.6%

Earnings growth rate

-6.4%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate22.0%
Return on equity-36.5%
Net Margin-2,957.6%
Last Earnings Update31 Jul 2023

Recent past performance updates

Recent updates

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Jan 05
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Sep 13
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Mar 27
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Jul 07
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn

Oct 28
We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn

Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?

Mar 21
Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Feb 14
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

Jan 10
Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

Dec 06
Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

Revenue & Expenses Breakdown

How e-therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:ETX Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Jul 230-1049
30 Apr 230-948
31 Jan 230-837
31 Oct 220-947
31 Jul 220-947
30 Apr 220-946
31 Jan 220-846
31 Oct 211-635
31 Jul 211-424
30 Apr 211-423
31 Jan 210-423
31 Oct 200-422
31 Jul 200-322
30 Apr 200-322
31 Jan 200-212
31 Oct 190-312
31 Jul 190-313
30 Apr 190-413
31 Jan 190-414
31 Oct 180-424
31 Jul 180-524
30 Apr 180-525
31 Jan 180-525
31 Oct 170-726
31 Jul 170-827
30 Apr 170-1129
31 Jan 170-13211
31 Oct 160-13211
31 Jul 160-12211
30 Apr 160-11211
31 Jan 160-9210
31 Oct 150-8210
31 Jul 150-829
30 Apr 150-829
31 Jan 150-829
31 Oct 140-728
31 Jul 140-727
30 Apr 140-626
31 Jan 140-515
31 Oct 130-515

Quality Earnings: ETX is currently unprofitable.

Growing Profit Margin: ETX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ETX is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.

Accelerating Growth: Unable to compare ETX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ETX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).


Return on Equity

High ROE: ETX has a negative Return on Equity (-36.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/10 12:44
End of Day Share Price 2024/05/08 00:00
Earnings2023/07/31
Annual Earnings2023/01/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

e-therapeutics plc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Philip MorrishGrowth Equities & Company Research
Paul CuddonNumis Securities Ltd.
Savvas NeophitouPanmure Liberum Historic (Panmure Gordon)